184 related articles for article (PubMed ID: 6242477)
1. Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.
Schally AV; Redding TW; Comaru-Schally AM
Med Oncol Tumor Pharmacother; 1984; 1(2):109-18. PubMed ID: 6242477
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6509-12. PubMed ID: 6458815
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH.
Schally AV; Redding TW; Comaru-Schally AM
Prostate; 1983; 4(6):545-52. PubMed ID: 6226942
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
Torres-Aleman I; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
[TBL] [Abstract][Full Text] [Related]
7. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Redding TW; Schally AV
Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.
de Quijada MG; Redding TW; Coy DH; Torres-Aleman I; Schally AV
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3485-8. PubMed ID: 6134284
[TBL] [Abstract][Full Text] [Related]
10. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1985 Apr; 82(8):2498-502. PubMed ID: 3157990
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV
Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973
[TBL] [Abstract][Full Text] [Related]
12. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
13. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
[TBL] [Abstract][Full Text] [Related]
15. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone.
Redding TW; Coy DH; Schally AV
Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1273-6. PubMed ID: 6803239
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Int J Cancer; 1994 Oct; 59(1):51-5. PubMed ID: 7927904
[TBL] [Abstract][Full Text] [Related]
17. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
Schally AV; Redding TW; Comaru-Schally AM
Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
Milovanovic SR; Radulovic S; Groot K; Schally AV
Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
